A new University of Cincinnati Cancer Center study has identified a particular strand of microRNA as a promising new target for overcoming breast cancer treatment resistance and improving outcomes.

Researchers want trustworthy, human-relevant models. Integrating automation and AI into organoid development workflows—or ...

The Life Science business of Merck KGaA, Darmstadt, Germany, has acquired HUB Organoids B.V. (HUB), as announced by MilliporeSigma, the U.S. and Canada business of Merck KGaA, Darmstadt, Germany in ...

Ackerman Cancer Center, a leading institution in personalized oncology care, is proud to announce its adoption of MyoStrain, a cutting-edge cardiac assessment technology. This partnership underscores ...

For the first time, researchers have cultivated stable tumor organoids from circulating breast cancer cells, improving ...

Tumor cells circulating in the blood are the 'germ cells' of breast cancer metastases. They are very rare and could not be propagated in the culture dish until now, which made research into therapy ...

Huch’s pancreatic organoids are now a promising avenue for disease modeling and generating precision medicines to treat ...

Pancreatic cancer is one of the most lethal cancers, with a 5-year overall survival rate of less than 10%. Despite the development of novel therapies in recent decades, current chemotherapeutic ...